Skip to content

Phage EU

default-logo
Menu
  • Home
  • Membership
  • About Us
  • About Phages
  • News
  • Contact Us
Read more about the article No antibiotics worked, so the woman turned to a natural enemy of bacteria to save her husband’s life
News

No antibiotics worked, so the woman turned to a natural enemy of bacteria to save her husband’s life

The use of bacteriophages could be an effective alternative to antibiotics in some cases, particularly when an infection is caused by a specific type of bacteria that is resistant to…

0 Comments
January 10, 2023
Read more about the article Bacteriophages among EFSA’s efforts to fight antibiotic resistance
News

Bacteriophages among EFSA’s efforts to fight antibiotic resistance

Improving animal health with phages is part of European Food Safety Authority (EFSA) strategies towards addressing AMR. AMR is a global challenge, and the use of antimicrobials in animals is…

0 Comments
January 10, 2023
Read more about the article Gut bacteriophages linked to improved cognitive ability in humans
News

Gut bacteriophages linked to improved cognitive ability in humans

The results of this study reinforce the consideration of bacteriophage viruses as influential actors in the relationship between the human microbiome and the brain”. The complex bacteriophage communities represent one…

0 Comments
January 9, 2023
Read more about the article Phage therapy: combating antibiotic-resistant bacteria with viruses
News

Phage therapy: combating antibiotic-resistant bacteria with viruses

Pseudomonas has become more sensitive to traditional antibiotics. This is one of the reasons why Yale researchers and Yale Medicine physicians are working together to help patients with personalized medicine…

0 Comments
January 9, 2023
  • Go to the previous page
  • 1
  • 2

Want to know more about PhageEU?

Contact Us
Copyright © 2024 Phage EU | Powered by Phage EU

Michael Fink, the Vice-President of PhageEU, is also the CEO of two companies, Phage Technology Center GmbH and FinkTec GmbH.

He is a Chemist and a Chemical Engineer by education with more than 20 years of experience in the area of farm to fork food safety with focus on product development and regulatory strategy in the food, milk, beer and beverage industry as well as in the dairy and life stock farming sector.

With this background and a passion for applied science, in 2013 he started to explore the use of bacteriophages as new approach to overcome existing problems in the above-mentioned fields.

His diverse expertise and commitment to lead his interdisciplinary teams to develop novel products and solutions, while always keeping a way for market authorisation in mind.

In his leadership within the cooperate boundaries, he is convinced that there is the demand for collaboration of the entire industry, the legislators and all other stake holders to bring bacteriophage technology, in all its different application facets, into a broad use. In some areas the legal basis for the specific use of bacteriophages is being developed and therefore it is important to support this process as the biotech / bacteriophage industry with all its very specific Know How.

He envisages a big contribution of bacteriophage technology to improve food safety, to make feed safer, in the reduction of food waste and to have an alternative strategy to reduce antibiotic use in different life stock applications.

Prof. Jarosław Dastych, the President of the PhageEU coalition, is also the Founder, CEO, and Board President of Proteon Pharmaceuticals S.A. His passion for bacteriophage research and his understanding of bacteriophage technology as a promising alternative for addressing rising antimicrobial resistance (AMR) have driven his work to realise the full potential of phages. His research spans immunology, toxicology, molecular biology, and the development of bacteriophage-based treatments.

Over 18 years ago, he founded Proteon Pharmaceuticals, leading to the development of a unique bacteriophage platform technology. This innovation provides sustainable solutions for bacterial disease management in animal farming, aquaculture, and poultry production, earning international recognition and numerous innovation awards. Prof. Dastych has managed twelve European R&D projects, published over 70 scientific papers, and co-authored 13 biotechnology patents, highlighting his extensive expertise and dedication to scientific progress.